Abstract
The coronavirus disease 2019 (COVID-19), which emerged from Wuhan, China, is now a pandemic, affecting across the globe. Bangladesh also is experiencing the rapid growth of COVID-19 infection and death cases started from 8th March 2020. The purpose of providing a simple yet effective explanatory model for prediction of the future evolution of the contagion and verification of the effectiveness of the containment and lockdown measures in Bangladesh. In this study, using a modified SIR (Susceptible-Infected-Recovered) model a forecast is generated to predict the trends of COVID-19 cases in Bangladesh. The epidemic model was proposed to accommodate the effects of lockdown and individual based precautionary measures. Data has been taken and analyzed for before and after the movement control order (MCO) and during the MCO period. Modified SIR model in this work offers us an idea how the outbreak would progress based on the current data. It also has estimated that, the peak in terms of the number of infected cases will start from last of June 2020. For the total population (100%) the model gets the peaks at 214875 (infected cases) and 7743 (death cases). For the 90% population, the model shows the peaks at 244356 (infected cases) and 9100 (death cases). Analysis revealed that the lockdown and recommended individual hygiene can slow down the outbreak but unable to eradicate the disease from the society. With the current infection and death rate and existing level of personal precautionary the number of infected individuals will be increasing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding involved.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Its an analysis conducted by the authors modified models. So no oversight body approval was required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.